Draganov V, Lazarov S
Vutr Boles. 2000;32(3):19-28.
Adult respiratory distress syndrome (ARDS) represents an excessively dangerous acute respiratory failure, as result of diffuse damage of alveolocapillary membranes in stiff noncompliant lungs. ARDS is a widely disseminated syndrome caused by severe etiologic factors. ARDS usually appears within 12 to 72 hours of an identifiable clinical event and progresses through three phases: 1. exudative phase; 2. alveolar membrane damage and pulmonary surfactant systems; and 3. proliferative phase. Nearly all of the deaths occur within 30 days of the onset of the syndrome. The mortality rate varies according to the causes and the age. ARDS progresses through three clinical phases: 1. basis respiratory failure; 2. progressive respiratory failure; and 3. total respiratory failure. The therapy of ARDS is complex. It consists of: 1. background general therapy of ARDS; 2. background supportive therapy of ARDS; 3. definitive therapy to interrupt mechanisms of inflammation and pulmonary injury; 4. new pharmacologic supportive therapy.
成人呼吸窘迫综合征(ARDS)是一种极其危险的急性呼吸衰竭,是由于僵硬且顺应性差的肺部肺泡毛细血管膜弥漫性损伤所致。ARDS是一种由严重病因引起的广泛传播的综合征。ARDS通常在可识别的临床事件发生后12至72小时内出现,并经历三个阶段:1. 渗出期;2. 肺泡膜损伤和肺表面活性物质系统;3. 增殖期。几乎所有死亡都发生在该综合征发病后的30天内。死亡率因病因和年龄而异。ARDS经历三个临床阶段:1. 基础呼吸衰竭;2. 进行性呼吸衰竭;3. 完全呼吸衰竭。ARDS的治疗很复杂。它包括:1. ARDS的背景综合治疗;2. ARDS的背景支持治疗;3. 中断炎症和肺损伤机制的确定性治疗;4. 新的药物支持治疗。